Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Uncategorized

UBS Maintains Buy on Walmart, Raises Price Target to $170

UBS analyst Michael Lasser maintains Walmart (NYSE:WMT) with a Buy and raises the price target from $160 to $170.

byBenzinga Newsdesk

May 19, 2021

1 minute read

UBS analyst Michael Lasser maintains Walmart (NYSE:WMT) with a Buy and raises the price target from $160 to $170.

Piper Sandler Maintains Overweight on Lululemon Athletica, Lowers Price Target to $445

By Benzinga Newsdesk

Today, 6:30 AM

Piper Sandler analyst Erinn Murphy maintains Lululemon Athletica (NASDAQ:LULU) with a Overweight and lowers the price target from $465 to $445.

LULU

News

‘Spider-Man: No Way Home’ Keeps Control Of US Box Office

By Phil Hall

Today, 6:30 AM

“Spider-Man: No Way Out” took the top ranking in the U.S. box office chart for the sixth time in seven weeks, with $10.4 million in ticket sales from 3,675 screens.

CMCSA

JP Morgan Initiates Coverage On Riskified with Neutral Rating, Announces Price Target of $29

By Benzinga Newsdesk

Today, 6:30 AM

JP Morgan analyst Tien-Tsin Huang initiates coverage on Riskified (NYSE:RSKD) with a Neutral rating and announces Price Target of $29.

RSKD

Gilead’s Yescarta Scores FDA Approval As First CAR T-Cell Therapy For Earlier Lymphoma

By Vandana Singh

Today, 6:30 AM

The FDA approved the expanded use of Gilead Sciences Inc’s (NASDAQ:GILD) Yescarta, a cell therapy made by the Kite Pharma unit. The…

GILD

UBS Maintains Buy on Walmart, Raises Price Target to $170

Related Posts

Piper Sandler Maintains Overweight on Lululemon Athletica, Lowers Price Target to $445

‘Spider-Man: No Way Home’ Keeps Control Of US Box Office

JP Morgan Initiates Coverage On Riskified with Neutral Rating, Announces Price Target of $29

Gilead’s Yescarta Scores FDA Approval As First CAR T-Cell Therapy For Earlier Lymphoma